Record time.

In an unusual turn of events, the NCCN has already updated its guidelines to include cisplatin + pemetrexed + pembro as first-line treatment of metastatic non-squamous, non-small cell lung cancer. In the renal cell carcinoma algorithm, nivolumab + ipilimumab is now the preferred first-line therapy for intermediate and high risk disease. In the meantime, we await the early stage endometrial cancer algorithm to be deciphered by Robert Langdon in the next Dan Brown thriller. | NCCN 2018